344 related articles for article (PubMed ID: 35053194)
21. Galectin-3 in Cardiovascular Diseases.
Blanda V; Bracale UM; Di Taranto MD; Fortunato G
Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33287402
[TBL] [Abstract][Full Text] [Related]
22. The association between galectin-3 and clinical parameters in patients with first acute myocardial infarction treated with primary percutaneous coronary angioplasty.
Szadkowska I; Wlazeł RN; Migała M; Szadkowski K; Zielińska M; Paradowski M; Pawlicki L
Cardiol J; 2013; 20(6):577-82. PubMed ID: 24338533
[TBL] [Abstract][Full Text] [Related]
23. Biomarkers in Atrial Fibrillation and Heart Failure.
Oikonomou E; Zografos T; Papamikroulis GA; Siasos G; Vogiatzi G; Theofilis P; Briasoulis A; Papaioannou S; Vavuranakis M; Gennimata V; Tousoulis D
Curr Med Chem; 2019; 26(5):873-887. PubMed ID: 28875838
[TBL] [Abstract][Full Text] [Related]
24. The Role of Galectin-3 in Predicting Congenital Heart Disease Outcome: A Review of the Literature.
Făgărășan A; Săsăran M; Gozar L; Crauciuc A; Bănescu C
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445687
[TBL] [Abstract][Full Text] [Related]
25. Galectin-3, a prognostic marker--and a therapeutic target?
Pereira AR; Menezes Falcão L
Rev Port Cardiol; 2015 Mar; 34(3):201-8. PubMed ID: 25746675
[TBL] [Abstract][Full Text] [Related]
26. Adverse Cardiac Remodelling after Acute Myocardial Infarction: Old and New Biomarkers.
Berezin AE; Berezin AA
Dis Markers; 2020; 2020():1215802. PubMed ID: 32626540
[TBL] [Abstract][Full Text] [Related]
27. Utility of galectin-3 as a prognostic biomarker in heart failure: where do we stand?
Srivatsan V; George M; Shanmugam E
Eur J Prev Cardiol; 2015 Sep; 22(9):1096-110. PubMed ID: 25268020
[TBL] [Abstract][Full Text] [Related]
28. Dynamics and prognostic role of galectin-3 in patients with advanced heart failure, during left ventricular assist device support and following heart transplantation.
Coromilas E; Que-Xu EC; Moore D; Kato TS; Wu C; Ji R; Givens R; Jorde UP; Takayama H; Naka Y; George I; Mancini D; Schulze PC
BMC Cardiovasc Disord; 2016 Jun; 16():138. PubMed ID: 27301475
[TBL] [Abstract][Full Text] [Related]
29. GDF-15, Galectin 3, Soluble ST2, and Risk of Mortality and Cardiovascular Events in CKD.
Tuegel C; Katz R; Alam M; Bhat Z; Bellovich K; de Boer I; Brosius F; Gadegbeku C; Gipson D; Hawkins J; Himmelfarb J; Ju W; Kestenbaum B; Kretzler M; Robinson-Cohen C; Steigerwalt S; Bansal N
Am J Kidney Dis; 2018 Oct; 72(4):519-528. PubMed ID: 29866459
[TBL] [Abstract][Full Text] [Related]
30. Galectin-3 Activation and Inhibition in Heart Failure and Cardiovascular Disease: An Update.
Suthahar N; Meijers WC; Silljé HHW; Ho JE; Liu FT; de Boer RA
Theranostics; 2018; 8(3):593-609. PubMed ID: 29344292
[TBL] [Abstract][Full Text] [Related]
31. Galectin-3 in acute coronary syndrome.
Agnello L; Bivona G; Lo Sasso B; Scazzone C; Bazan V; Bellia C; Ciaccio M
Clin Biochem; 2017 Sep; 50(13-14):797-803. PubMed ID: 28456545
[TBL] [Abstract][Full Text] [Related]
32. Galectin-3 in Acute Myocardial Infarction Patients with Atrial Fibrillation.
Stanojevic D; Apostolovic S; Stokanovic D; Momčilović S; Jevtovic-Stoimenov T; Salinger-Martinovic S; Kostic T; Nikolic VN
Med Princ Pract; 2019; 28(3):284-290. PubMed ID: 30726858
[TBL] [Abstract][Full Text] [Related]
33. Galectin-3: a modifiable risk factor in heart failure.
de Boer RA; van der Velde AR; Mueller C; van Veldhuisen DJ; Anker SD; Peacock WF; Adams KF; Maisel A
Cardiovasc Drugs Ther; 2014 Jun; 28(3):237-46. PubMed ID: 24789662
[TBL] [Abstract][Full Text] [Related]
34. Value of Galectin-3 in Acute Myocardial Infarction.
Li M; Yuan Y; Guo K; Lao Y; Huang X; Feng L
Am J Cardiovasc Drugs; 2020 Aug; 20(4):333-342. PubMed ID: 31784887
[TBL] [Abstract][Full Text] [Related]
35. A Scoping Review of Galectin-3 as a Biomarker of Cardiovascular Diseases in Pediatric Populations.
Smereczyńska-Wierzbicka E; Pietrzak R; Werner B
Int J Environ Res Public Health; 2022 Apr; 19(7):. PubMed ID: 35410028
[TBL] [Abstract][Full Text] [Related]
36. Galectin-3 in heart failure with preserved ejection fraction.
de Boer RA; Edelmann F; Cohen-Solal A; Mamas MA; Maisel A; Pieske B
Eur J Heart Fail; 2013 Oct; 15(10):1095-101. PubMed ID: 23650131
[TBL] [Abstract][Full Text] [Related]
37. Time-course analysis of cardiac and serum galectin-3 in viral myocarditis after an encephalomyocarditis virus inoculation.
Noguchi K; Tomita H; Kanayama T; Niwa A; Hatano Y; Hoshi M; Sugie S; Okada H; Niwa M; Hara A
PLoS One; 2019; 14(1):e0210971. PubMed ID: 30673749
[TBL] [Abstract][Full Text] [Related]
38. Personalizing biomarker strategies in heart failure with galectin-3.
Sherwi N; Merali S; Wong K
Future Cardiol; 2012 Nov; 8(6):885-94. PubMed ID: 23176690
[TBL] [Abstract][Full Text] [Related]
39. Serial measurement of galectin-3 in patients with chronic heart failure: results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study.
Motiwala SR; Szymonifka J; Belcher A; Weiner RB; Baggish AL; Sluss P; Gaggin HK; Bhardwaj A; Januzzi JL
Eur J Heart Fail; 2013 Oct; 15(10):1157-63. PubMed ID: 23666680
[TBL] [Abstract][Full Text] [Related]
40. Myocardial and Serum Galectin-3 Expression Dynamics Marks Post-Myocardial Infarction Cardiac Remodelling.
Sharma UC; Mosleh W; Chaudhari MR; Katkar R; Weil B; Evelo C; Cimato TR; Pokharel S; Blankesteijn WM; Suzuki G
Heart Lung Circ; 2017 Jul; 26(7):736-745. PubMed ID: 28094123
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
